Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a treatment for people with spontaneous supratentorial intracerebral hemorrhage ICH, a serious type of stroke caused by bleeding in the brain. The study is a phase III randomized controlled trial that will involve 768 participants to compare a new minimally invasive surgery combined with a clot-dissolving drug against standard medical care. This trial aims to assess the safety and effectiveness of using tenecteplase to liquefy and drain brain hematomas, potentially improving recovery outcomes. Participants will be randomly assigned to one of two groups. One group will receive minimally invasive stereotactic catheter placement followed by the local injection of tenecteplase to liquefy and drain the hematoma, with doses of 0.5 mg given up to four times over several days. The other group will receive standard medical treatment in line with current guidelines. The surgery uses imaging to target the hematoma, and after catheter placement, tenecteplase is carefully administered through the catheter with close monitoring. Throughout the study, participants will undergo regular assessments including neurological exams, brain imaging, and functional outcome evaluations up to 180 days after treatment. The main measurement is the modified Rankin Score assessing disability and recovery. Other outcomes include neurological improvement, hematoma size, mortality, and quality of life. Follow-up visits may be conducted face-to-face or remotely, and researchers will carefully monitor safety and treatment effects during this period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an artificial intelligence-based multimodal cognitive screening system to identify mild cognitive impairment MCI related to diabetes early in patients with type 2 diabetes mellitus T2DM. This observational study follows participants for 3 to 5 years to assess the systems accuracy and feasibility. The study also explores how diabetic metabolic indicators, such as glycemic variability and HbA1c levels, relate to changes in cognitive function, aiming to improve early detection and intervention for cognitive decline in T2DM patients. Participants are observed without additional interventions over the 3 to 5 years of follow-up. The study includes groups of participants with normal cognition and those with mild cognitive impairment. Cognitive status data are collected at the beginning and end of the study period, with no study drug or treatment administered. During the study, participants undergo cognitive assessments and monitoring of diabetic metabolic factors. Researchers measure the accuracy of the AI screening system in early detection and track the rate of cognitive decline over the follow-up period. The study also evaluates the predictive value of combining multiple types of data. Participants remain under observation with regular assessments, helping to understand the relationship between diabetes and cognitive changes over time.
Actively Recruiting
Nausea and vomiting in pregnancy NVP is a common and challenging problem during the first trimester, affecting the quality of life for many pregnant women. This research aims to evaluate the clinical effectiveness and safety of thumbtack needle TN therapy, a type of acupuncture, for treating NVP. The study is a multi-center, large-sample, randomized, controlled, and triple-blinded clinical trial designed to provide high-quality evidence on this treatment. The trial compares thumbtack needle therapy with a sham thumbtack needle treatment. TN involves applying small intradermal needles to specific acupuncture points, which are kept in place for 3 days with patients pressing the needles multiple times daily. Treatments occur every 3 days for a total of 5 sessions over 15 days. The sham treatment mimics the procedure without actual needle penetration and without pressing during retention. Participants will be closely monitored throughout the study with assessments including nausea and vomiting severity, quality of life, anxiety, depression, sleep quality, weight changes, blood tests for electrolytes, liver and kidney function, thyroid hormones, and pregnancy and neonatal outcomes. Safety and patient satisfaction will also be evaluated. The primary outcome is the change in nausea and vomiting severity measured by the PUQE scale from baseline to day 15. Follow-up continues up to 42 days postpartum to observe pregnancy complications and neonatal health.